| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Transplantation | 76 | 2024 | 293 | 27.060 |
Why?
|
| Extracorporeal Membrane Oxygenation | 29 | 2024 | 184 | 9.470 |
Why?
|
| Lung | 41 | 2024 | 1273 | 5.790 |
Why?
|
| Primary Graft Dysfunction | 9 | 2024 | 39 | 4.680 |
Why?
|
| Perfusion | 15 | 2024 | 237 | 3.190 |
Why?
|
| Tissue and Organ Procurement | 10 | 2024 | 352 | 3.120 |
Why?
|
| Tissue Donors | 18 | 2024 | 496 | 2.870 |
Why?
|
| Retrospective Studies | 54 | 2024 | 9127 | 2.110 |
Why?
|
| Graft Survival | 13 | 2024 | 902 | 2.100 |
Why?
|
| Heart-Lung Transplantation | 2 | 2024 | 19 | 1.770 |
Why?
|
| Respiratory Insufficiency | 7 | 2022 | 161 | 1.770 |
Why?
|
| Glycocalyx | 2 | 2024 | 4 | 1.730 |
Why?
|
| Glucuronidase | 2 | 2024 | 23 | 1.720 |
Why?
|
| Syndecan-1 | 2 | 2023 | 16 | 1.710 |
Why?
|
| Reperfusion Injury | 5 | 2024 | 141 | 1.640 |
Why?
|
| Organ Preservation | 7 | 2024 | 108 | 1.630 |
Why?
|
| Humans | 111 | 2024 | 89613 | 1.550 |
Why?
|
| Transplant Recipients | 9 | 2024 | 137 | 1.540 |
Why?
|
| Postoperative Complications | 10 | 2024 | 2297 | 1.510 |
Why?
|
| Liver Diseases | 2 | 2022 | 242 | 1.360 |
Why?
|
| Donor Selection | 4 | 2024 | 75 | 1.330 |
Why?
|
| Lung Diseases | 3 | 2020 | 273 | 1.310 |
Why?
|
| Heparin | 7 | 2022 | 185 | 1.280 |
Why?
|
| Heart Transplantation | 2 | 2024 | 717 | 1.190 |
Why?
|
| Liver Transplantation | 3 | 2024 | 1172 | 1.150 |
Why?
|
| Adult | 42 | 2024 | 26704 | 1.130 |
Why?
|
| Antithrombins | 3 | 2022 | 16 | 1.110 |
Why?
|
| Registries | 6 | 2024 | 791 | 1.110 |
Why?
|
| Treatment Outcome | 27 | 2024 | 8218 | 1.000 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2023 | 158 | 0.990 |
Why?
|
| Catheterization | 4 | 2020 | 237 | 0.970 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2022 | 55 | 0.950 |
Why?
|
| Thoracic Surgical Procedures | 2 | 2022 | 55 | 0.930 |
Why?
|
| Lung Injury | 3 | 2022 | 53 | 0.920 |
Why?
|
| Macrophages, Alveolar | 2 | 2021 | 57 | 0.920 |
Why?
|
| Male | 54 | 2024 | 42488 | 0.910 |
Why?
|
| Anticoagulants | 6 | 2021 | 428 | 0.900 |
Why?
|
| Pulmonary Veno-Occlusive Disease | 1 | 2023 | 8 | 0.890 |
Why?
|
| Cannula | 2 | 2020 | 50 | 0.880 |
Why?
|
| Cystic Fibrosis | 2 | 2021 | 115 | 0.870 |
Why?
|
| Jugular Veins | 3 | 2020 | 74 | 0.870 |
Why?
|
| Incidental Findings | 1 | 2024 | 98 | 0.860 |
Why?
|
| Eisenmenger Complex | 1 | 2023 | 6 | 0.860 |
Why?
|
| Graft Rejection | 10 | 2024 | 1072 | 0.860 |
Why?
|
| Hemorrhage | 3 | 2022 | 284 | 0.850 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2023 | 73 | 0.850 |
Why?
|
| Middle Aged | 40 | 2024 | 26012 | 0.840 |
Why?
|
| Thrombosis | 4 | 2022 | 301 | 0.830 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 5 | 2023 | 199 | 0.820 |
Why?
|
| Intraoperative Care | 1 | 2023 | 83 | 0.810 |
Why?
|
| Bronchiolitis | 1 | 2022 | 8 | 0.810 |
Why?
|
| Situs Inversus | 1 | 2022 | 15 | 0.810 |
Why?
|
| Bronchiolitis, Viral | 1 | 2022 | 5 | 0.800 |
Why?
|
| Female | 46 | 2024 | 46401 | 0.780 |
Why?
|
| Thoracic Surgery | 1 | 2022 | 45 | 0.770 |
Why?
|
| Risk Factors | 17 | 2024 | 5517 | 0.760 |
Why?
|
| Endothelium | 1 | 2021 | 57 | 0.760 |
Why?
|
| Extracorporeal Circulation | 6 | 2023 | 34 | 0.750 |
Why?
|
| Femoral Vein | 2 | 2020 | 39 | 0.740 |
Why?
|
| Plasmapheresis | 1 | 2021 | 25 | 0.740 |
Why?
|
| Heart Defects, Congenital | 1 | 2024 | 365 | 0.740 |
Why?
|
| Hyperammonemia | 1 | 2021 | 13 | 0.740 |
Why?
|
| Dabigatran | 1 | 2020 | 25 | 0.730 |
Why?
|
| Subclavian Vein | 1 | 2020 | 15 | 0.720 |
Why?
|
| End Stage Liver Disease | 1 | 2021 | 61 | 0.710 |
Why?
|
| Survival Rate | 11 | 2024 | 1887 | 0.710 |
Why?
|
| Jehovah's Witnesses | 1 | 2020 | 20 | 0.700 |
Why?
|
| Hospitals, High-Volume | 1 | 2020 | 38 | 0.690 |
Why?
|
| Immunologic Memory | 1 | 2021 | 163 | 0.690 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2023 | 597 | 0.680 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2020 | 264 | 0.670 |
Why?
|
| Hypertension, Pulmonary | 1 | 2023 | 354 | 0.670 |
Why?
|
| Biomarkers | 3 | 2023 | 1768 | 0.670 |
Why?
|
| Mice, Inbred C57BL | 4 | 2024 | 3240 | 0.670 |
Why?
|
| Peptide Fragments | 1 | 2021 | 462 | 0.650 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 141 | 0.650 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2022 | 447 | 0.650 |
Why?
|
| Disease Models, Animal | 13 | 2022 | 2384 | 0.640 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2019 | 76 | 0.620 |
Why?
|
| Myocardial Infarction | 6 | 2022 | 375 | 0.610 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 642 | 0.610 |
Why?
|
| Follow-Up Studies | 12 | 2024 | 3659 | 0.600 |
Why?
|
| Waiting Lists | 5 | 2023 | 185 | 0.590 |
Why?
|
| Pulmonary Artery | 3 | 2018 | 320 | 0.570 |
Why?
|
| Time Factors | 16 | 2024 | 5337 | 0.550 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 433 | 0.540 |
Why?
|
| Staphylococcal Infections | 1 | 2019 | 271 | 0.520 |
Why?
|
| Staphylococcus aureus | 1 | 2019 | 276 | 0.520 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 425 | 0.500 |
Why?
|
| Kidney Transplantation | 1 | 2022 | 854 | 0.500 |
Why?
|
| HIV Infections | 1 | 2024 | 846 | 0.480 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 1125 | 0.480 |
Why?
|
| Child | 10 | 2024 | 7216 | 0.460 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 149 | 0.450 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 168 | 0.440 |
Why?
|
| Heart Arrest | 2 | 2016 | 277 | 0.440 |
Why?
|
| Erythrocyte Transfusion | 3 | 2023 | 72 | 0.430 |
Why?
|
| Cold Ischemia | 1 | 2013 | 18 | 0.430 |
Why?
|
| Severity of Illness Index | 8 | 2022 | 1851 | 0.430 |
Why?
|
| Heart-Assist Devices | 7 | 2016 | 763 | 0.420 |
Why?
|
| Vascular Resistance | 1 | 2013 | 103 | 0.420 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 384 | 0.410 |
Why?
|
| Animals | 24 | 2024 | 27481 | 0.400 |
Why?
|
| Venous Thrombosis | 4 | 2019 | 252 | 0.390 |
Why?
|
| United States | 11 | 2024 | 7050 | 0.380 |
Why?
|
| Prognosis | 6 | 2024 | 3785 | 0.380 |
Why?
|
| Transplantation, Homologous | 3 | 2024 | 995 | 0.380 |
Why?
|
| Platelet Transfusion | 2 | 2021 | 16 | 0.380 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 2364 | 0.370 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2022 | 479 | 0.360 |
Why?
|
| Heart-Lung Machine | 3 | 2016 | 5 | 0.360 |
Why?
|
| Warm Ischemia | 3 | 2023 | 31 | 0.350 |
Why?
|
| Pulmonary Emphysema | 1 | 2010 | 37 | 0.350 |
Why?
|
| Rats | 5 | 2023 | 4041 | 0.340 |
Why?
|
| Hospital Mortality | 7 | 2021 | 399 | 0.340 |
Why?
|
| Aged | 16 | 2024 | 19158 | 0.330 |
Why?
|
| Reoperation | 3 | 2024 | 603 | 0.330 |
Why?
|
| Organ Transplantation | 2 | 2024 | 280 | 0.320 |
Why?
|
| Infant | 5 | 2023 | 3176 | 0.320 |
Why?
|
| Hemodynamics | 6 | 2017 | 731 | 0.320 |
Why?
|
| Inflammation | 4 | 2023 | 975 | 0.310 |
Why?
|
| Pneumonectomy | 1 | 2010 | 209 | 0.300 |
Why?
|
| Age Factors | 7 | 2021 | 1877 | 0.290 |
Why?
|
| Surgical Wound Infection | 2 | 2023 | 201 | 0.290 |
Why?
|
| Immunosuppressive Agents | 3 | 2022 | 976 | 0.290 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2022 | 61 | 0.290 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 836 | 0.270 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2022 | 951 | 0.250 |
Why?
|
| Swine | 3 | 2017 | 588 | 0.250 |
Why?
|
| Ventricular Remodeling | 3 | 2016 | 107 | 0.250 |
Why?
|
| Brain Death | 2 | 2024 | 82 | 0.250 |
Why?
|
| Child, Preschool | 3 | 2022 | 3756 | 0.250 |
Why?
|
| Death | 2 | 2023 | 86 | 0.250 |
Why?
|
| Adolescent | 8 | 2022 | 9305 | 0.240 |
Why?
|
| Myocytes, Cardiac | 3 | 2019 | 314 | 0.240 |
Why?
|
| Recovery of Function | 6 | 2022 | 293 | 0.240 |
Why?
|
| Respiration, Artificial | 4 | 2020 | 351 | 0.240 |
Why?
|
| Herpesvirus 4, Human | 2 | 2022 | 120 | 0.230 |
Why?
|
| Myocardium | 4 | 2016 | 572 | 0.230 |
Why?
|
| Scleroderma, Systemic | 1 | 2024 | 53 | 0.230 |
Why?
|
| Cohort Studies | 5 | 2023 | 2878 | 0.230 |
Why?
|
| Acute Disease | 3 | 2023 | 842 | 0.230 |
Why?
|
| Sheep | 8 | 2016 | 251 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 849 | 0.230 |
Why?
|
| Equipment Design | 5 | 2021 | 420 | 0.230 |
Why?
|
| Hemoglobins | 3 | 2020 | 193 | 0.230 |
Why?
|
| Bronchiolitis Obliterans | 2 | 2020 | 33 | 0.230 |
Why?
|
| HIV | 1 | 2024 | 48 | 0.220 |
Why?
|
| Ischemia | 2 | 2022 | 252 | 0.220 |
Why?
|
| Blood Group Incompatibility | 1 | 2023 | 20 | 0.220 |
Why?
|
| Filgrastim | 1 | 2023 | 57 | 0.220 |
Why?
|
| Cytokines | 3 | 2022 | 806 | 0.220 |
Why?
|
| Isoantibodies | 2 | 2023 | 119 | 0.220 |
Why?
|
| Carbon Dioxide | 2 | 2022 | 201 | 0.220 |
Why?
|
| Liver Failure | 1 | 2023 | 67 | 0.220 |
Why?
|
| HLA Antigens | 2 | 2023 | 227 | 0.210 |
Why?
|
| Ambulatory Care | 2 | 2016 | 186 | 0.210 |
Why?
|
| Organ Size | 2 | 2024 | 370 | 0.210 |
Why?
|
| Telomerase | 1 | 2023 | 67 | 0.210 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2023 | 60 | 0.210 |
Why?
|
| F-Box Proteins | 1 | 2022 | 11 | 0.210 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2023 | 85 | 0.210 |
Why?
|
| Ventricular Function, Left | 3 | 2019 | 607 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2024 | 2668 | 0.200 |
Why?
|
| Lymphopenia | 1 | 2022 | 30 | 0.200 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2023 | 118 | 0.200 |
Why?
|
| Endothelium, Vascular | 1 | 2024 | 432 | 0.200 |
Why?
|
| Alemtuzumab | 1 | 2022 | 85 | 0.200 |
Why?
|
| Ultrasonography, Doppler, Duplex | 2 | 2019 | 42 | 0.200 |
Why?
|
| Hypotension | 1 | 2022 | 71 | 0.200 |
Why?
|
| Databases, Factual | 2 | 2024 | 860 | 0.200 |
Why?
|
| Hirudins | 1 | 2021 | 5 | 0.190 |
Why?
|
| Quality of Life | 3 | 2024 | 1673 | 0.190 |
Why?
|
| Pulmonary Ventilation | 1 | 2021 | 33 | 0.190 |
Why?
|
| Artificial Organs | 1 | 2021 | 4 | 0.190 |
Why?
|
| Plasma | 1 | 2021 | 51 | 0.190 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2021 | 32 | 0.190 |
Why?
|
| Drowning | 1 | 2021 | 3 | 0.190 |
Why?
|
| Asphyxia | 1 | 2021 | 11 | 0.190 |
Why?
|
| Critical Illness | 2 | 2022 | 307 | 0.190 |
Why?
|
| Wearable Electronic Devices | 1 | 2021 | 26 | 0.180 |
Why?
|
| Tissue Culture Techniques | 1 | 2021 | 81 | 0.180 |
Why?
|
| Shock, Cardiogenic | 1 | 2022 | 107 | 0.180 |
Why?
|
| Complement C1q | 1 | 2020 | 11 | 0.180 |
Why?
|
| Coculture Techniques | 1 | 2021 | 175 | 0.180 |
Why?
|
| Sheep, Domestic | 3 | 2021 | 9 | 0.180 |
Why?
|
| Bronchi | 1 | 2022 | 229 | 0.180 |
Why?
|
| Credentialing | 1 | 2020 | 14 | 0.180 |
Why?
|
| Abatacept | 2 | 2022 | 85 | 0.180 |
Why?
|
| Cellular Senescence | 1 | 2021 | 100 | 0.180 |
Why?
|
| Antifungal Agents | 1 | 2021 | 122 | 0.180 |
Why?
|
| Datasets as Topic | 1 | 2020 | 75 | 0.180 |
Why?
|
| Cell Death | 1 | 2021 | 261 | 0.180 |
Why?
|
| Models, Animal | 4 | 2015 | 276 | 0.180 |
Why?
|
| Hydromorphone | 1 | 2020 | 11 | 0.180 |
Why?
|
| Bronchoscopy | 1 | 2022 | 162 | 0.180 |
Why?
|
| Acute Kidney Injury | 1 | 2024 | 316 | 0.180 |
Why?
|
| Transplants | 1 | 2020 | 41 | 0.170 |
Why?
|
| Travel | 1 | 2020 | 71 | 0.170 |
Why?
|
| Anesthetics | 1 | 2020 | 53 | 0.170 |
Why?
|
| Fentanyl | 1 | 2020 | 71 | 0.170 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 276 | 0.170 |
Why?
|
| Social Class | 1 | 2020 | 137 | 0.170 |
Why?
|
| Cyclosporine | 1 | 2020 | 237 | 0.170 |
Why?
|
| Glucocorticoids | 1 | 2022 | 357 | 0.170 |
Why?
|
| Young Adult | 8 | 2020 | 6368 | 0.170 |
Why?
|
| Mice, Knockout | 1 | 2024 | 2014 | 0.170 |
Why?
|
| Geography | 1 | 2020 | 227 | 0.170 |
Why?
|
| Point-of-Care Systems | 1 | 2020 | 145 | 0.170 |
Why?
|
| Respiration | 1 | 2021 | 267 | 0.170 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2020 | 111 | 0.170 |
Why?
|
| Perception | 1 | 2020 | 179 | 0.160 |
Why?
|
| Methicillin | 1 | 2019 | 4 | 0.160 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1008 | 0.160 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2019 | 18 | 0.160 |
Why?
|
| Clindamycin | 1 | 2019 | 15 | 0.160 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2019 | 53 | 0.160 |
Why?
|
| Vena Cava, Inferior | 1 | 2020 | 144 | 0.160 |
Why?
|
| Burkholderia Infections | 1 | 2018 | 2 | 0.160 |
Why?
|
| Decontamination | 1 | 2018 | 9 | 0.160 |
Why?
|
| Hypnotics and Sedatives | 1 | 2020 | 132 | 0.160 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2018 | 25 | 0.160 |
Why?
|
| Interinstitutional Relations | 1 | 2018 | 29 | 0.160 |
Why?
|
| Heart | 1 | 2022 | 574 | 0.160 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2019 | 132 | 0.150 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 1725 | 0.150 |
Why?
|
| Anesthesia | 1 | 2020 | 166 | 0.150 |
Why?
|
| Surgical Mesh | 1 | 2019 | 124 | 0.150 |
Why?
|
| Embolectomy | 1 | 2017 | 6 | 0.150 |
Why?
|
| Intensive Care Units | 2 | 2022 | 397 | 0.150 |
Why?
|
| Tissue Scaffolds | 1 | 2019 | 116 | 0.150 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2021 | 262 | 0.150 |
Why?
|
| Mitochondria, Liver | 1 | 2017 | 28 | 0.150 |
Why?
|
| Aortic Valve Stenosis | 1 | 2019 | 144 | 0.150 |
Why?
|
| Hospitals, Pediatric | 1 | 2019 | 117 | 0.150 |
Why?
|
| Pulmonary Fibrosis | 1 | 2019 | 138 | 0.150 |
Why?
|
| Telomere | 3 | 2023 | 119 | 0.150 |
Why?
|
| Sphingosine | 1 | 2018 | 74 | 0.150 |
Why?
|
| Lysophospholipids | 1 | 2018 | 66 | 0.150 |
Why?
|
| Population Surveillance | 1 | 2019 | 216 | 0.150 |
Why?
|
| Rare Diseases | 1 | 2018 | 69 | 0.150 |
Why?
|
| Aortic Valve | 1 | 2019 | 244 | 0.150 |
Why?
|
| Mice | 4 | 2024 | 11832 | 0.150 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2019 | 118 | 0.140 |
Why?
|
| Allografts | 3 | 2023 | 183 | 0.140 |
Why?
|
| Tissue Engineering | 1 | 2019 | 191 | 0.140 |
Why?
|
| Infant, Newborn | 2 | 2023 | 2488 | 0.140 |
Why?
|
| Logistic Models | 1 | 2020 | 1214 | 0.140 |
Why?
|
| Immunohistochemistry | 1 | 2021 | 1798 | 0.140 |
Why?
|
| Bleomycin | 1 | 2017 | 103 | 0.140 |
Why?
|
| Plasma Exchange | 1 | 2017 | 30 | 0.140 |
Why?
|
| Veins | 1 | 2017 | 95 | 0.140 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2016 | 31 | 0.140 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2016 | 48 | 0.130 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 401 | 0.130 |
Why?
|
| Catheters | 1 | 2016 | 83 | 0.130 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2017 | 136 | 0.130 |
Why?
|
| Lipopolysaccharides | 1 | 2017 | 294 | 0.130 |
Why?
|
| Lung Volume Measurements | 1 | 2015 | 20 | 0.130 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2016 | 112 | 0.130 |
Why?
|
| Arteries | 1 | 2017 | 179 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 1394 | 0.130 |
Why?
|
| Cardiac Catheters | 1 | 2015 | 13 | 0.130 |
Why?
|
| Lung Compliance | 1 | 2015 | 15 | 0.130 |
Why?
|
| Heart Ventricles | 2 | 2022 | 779 | 0.130 |
Why?
|
| Baltimore | 1 | 2015 | 40 | 0.130 |
Why?
|
| Liver Failure, Acute | 1 | 2015 | 39 | 0.130 |
Why?
|
| Acute Lung Injury | 1 | 2016 | 64 | 0.130 |
Why?
|
| Exercise Tolerance | 2 | 2017 | 54 | 0.130 |
Why?
|
| Life Support Care | 1 | 2015 | 50 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 652 | 0.120 |
Why?
|
| Renal Insufficiency | 1 | 2016 | 98 | 0.120 |
Why?
|
| Multidetector Computed Tomography | 1 | 2015 | 59 | 0.120 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2018 | 275 | 0.120 |
Why?
|
| Critical Pathways | 1 | 2015 | 37 | 0.120 |
Why?
|
| Assisted Circulation | 1 | 2015 | 16 | 0.120 |
Why?
|
| Gastritis | 1 | 2015 | 36 | 0.120 |
Why?
|
| Dyspnea | 2 | 2017 | 76 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 305 | 0.120 |
Why?
|
| Signal Transduction | 2 | 2016 | 3397 | 0.120 |
Why?
|
| Pulmonary Embolism | 1 | 2017 | 229 | 0.120 |
Why?
|
| Mass Screening | 1 | 2019 | 645 | 0.120 |
Why?
|
| Incidence | 4 | 2023 | 1598 | 0.120 |
Why?
|
| Fontan Procedure | 1 | 2015 | 56 | 0.120 |
Why?
|
| Clinical Competence | 1 | 2020 | 791 | 0.120 |
Why?
|
| Lung Diseases, Fungal | 1 | 2014 | 18 | 0.120 |
Why?
|
| Societies, Medical | 1 | 2018 | 582 | 0.120 |
Why?
|
| Mucormycosis | 1 | 2014 | 15 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2018 | 402 | 0.110 |
Why?
|
| Biocompatible Materials | 1 | 2015 | 198 | 0.110 |
Why?
|
| Cardiac Catheterization | 1 | 2015 | 303 | 0.110 |
Why?
|
| Amiodarone | 1 | 2013 | 14 | 0.110 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2016 | 222 | 0.110 |
Why?
|
| Lidocaine | 1 | 2013 | 65 | 0.110 |
Why?
|
| Organ Preservation Solutions | 1 | 2013 | 28 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 795 | 0.110 |
Why?
|
| Venous Thromboembolism | 1 | 2015 | 159 | 0.110 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2015 | 237 | 0.100 |
Why?
|
| Cold Temperature | 1 | 2013 | 160 | 0.100 |
Why?
|
| Maryland | 3 | 2017 | 43 | 0.100 |
Why?
|
| Obesity, Morbid | 1 | 2015 | 238 | 0.100 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 472 | 0.100 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 331 | 0.100 |
Why?
|
| Calcium Signaling | 1 | 2013 | 138 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2023 | 205 | 0.100 |
Why?
|
| Regional Blood Flow | 1 | 2012 | 198 | 0.100 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2013 | 200 | 0.100 |
Why?
|
| Ventilators, Mechanical | 1 | 2011 | 35 | 0.100 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2015 | 602 | 0.100 |
Why?
|
| Risk Assessment | 4 | 2020 | 2304 | 0.090 |
Why?
|
| Rats, Inbred Lew | 2 | 2022 | 193 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2020 | 1060 | 0.090 |
Why?
|
| Residual Volume | 1 | 2010 | 2 | 0.090 |
Why?
|
| Access to Information | 1 | 2010 | 28 | 0.090 |
Why?
|
| Kidney | 1 | 2016 | 1147 | 0.090 |
Why?
|
| Databases as Topic | 1 | 2010 | 94 | 0.090 |
Why?
|
| Forced Expiratory Volume | 1 | 2010 | 125 | 0.090 |
Why?
|
| Proteomics | 2 | 2023 | 231 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 358 | 0.080 |
Why?
|
| Heart Failure | 1 | 2019 | 1191 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2022 | 699 | 0.080 |
Why?
|
| Models, Biological | 1 | 2015 | 1762 | 0.080 |
Why?
|
| Prosthesis Design | 3 | 2015 | 298 | 0.080 |
Why?
|
| Blood Transfusion | 2 | 2022 | 170 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 2646 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 434 | 0.070 |
Why?
|
| Algorithms | 1 | 2015 | 1903 | 0.070 |
Why?
|
| Research Design | 1 | 2010 | 589 | 0.070 |
Why?
|
| Apoptosis | 3 | 2022 | 1717 | 0.070 |
Why?
|
| Oxygen | 3 | 2016 | 744 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2020 | 952 | 0.070 |
Why?
|
| Blood Coagulation | 2 | 2017 | 91 | 0.060 |
Why?
|
| Pandemics | 2 | 2021 | 777 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1705 | 0.060 |
Why?
|
| Europe | 1 | 2024 | 322 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2015 | 123 | 0.060 |
Why?
|
| Linear Models | 2 | 2015 | 421 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2022 | 2021 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2016 | 1130 | 0.050 |
Why?
|
| Heart Atria | 2 | 2016 | 282 | 0.050 |
Why?
|
| Sodium-Calcium Exchanger | 2 | 2013 | 22 | 0.050 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2 | 2013 | 25 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 6771 | 0.050 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2022 | 7 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2023 | 166 | 0.050 |
Why?
|
| Neutropenia | 1 | 2023 | 214 | 0.050 |
Why?
|
| Mice, Inbred DBA | 1 | 2022 | 149 | 0.050 |
Why?
|
| Ulcer | 1 | 2022 | 37 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2015 | 341 | 0.050 |
Why?
|
| Calcium-Binding Proteins | 2 | 2013 | 121 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2022 | 90 | 0.050 |
Why?
|
| Fetus | 1 | 2023 | 232 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2023 | 234 | 0.050 |
Why?
|
| Necrosis | 1 | 2022 | 210 | 0.050 |
Why?
|
| Nasopharynx | 1 | 2022 | 50 | 0.050 |
Why?
|
| Viremia | 1 | 2022 | 49 | 0.050 |
Why?
|
| Antibodies | 1 | 2023 | 353 | 0.050 |
Why?
|
| Telomere Shortening | 1 | 2021 | 25 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 1727 | 0.050 |
Why?
|
| Voriconazole | 1 | 2021 | 18 | 0.050 |
Why?
|
| Myocardial Reperfusion | 1 | 2021 | 28 | 0.050 |
Why?
|
| Infliximab | 1 | 2022 | 159 | 0.050 |
Why?
|
| Blood Gas Analysis | 1 | 2021 | 38 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2023 | 255 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2022 | 172 | 0.050 |
Why?
|
| Cell Differentiation | 2 | 2022 | 1529 | 0.050 |
Why?
|
| Major Histocompatibility Complex | 1 | 2021 | 84 | 0.050 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2021 | 127 | 0.050 |
Why?
|
| Hydrogen Peroxide | 1 | 2022 | 158 | 0.050 |
Why?
|
| Pulmonary Circulation | 1 | 2021 | 90 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2021 | 101 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 394 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 1 | 2022 | 309 | 0.050 |
Why?
|
| Nitriles | 1 | 2021 | 156 | 0.050 |
Why?
|
| Deoxyadenine Nucleotides | 1 | 2020 | 2 | 0.050 |
Why?
|
| Alarmins | 1 | 2020 | 5 | 0.050 |
Why?
|
| Triazoles | 1 | 2021 | 104 | 0.050 |
Why?
|
| Heat-Shock Proteins | 1 | 2022 | 183 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2022 | 318 | 0.050 |
Why?
|
| Survivors | 1 | 2022 | 234 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2022 | 782 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2022 | 1090 | 0.040 |
Why?
|
| Pennsylvania | 1 | 2019 | 95 | 0.040 |
Why?
|
| Pyridines | 1 | 2021 | 298 | 0.040 |
Why?
|
| Propensity Score | 1 | 2020 | 149 | 0.040 |
Why?
|
| Cell Survival | 1 | 2022 | 983 | 0.040 |
Why?
|
| Electrocardiography | 1 | 2022 | 497 | 0.040 |
Why?
|
| Delirium | 1 | 2020 | 72 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 416 | 0.040 |
Why?
|
| Cause of Death | 1 | 2020 | 269 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 655 | 0.040 |
Why?
|
| Critical Care | 1 | 2022 | 384 | 0.040 |
Why?
|
| Patient Selection | 1 | 2022 | 677 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 1 | 2018 | 75 | 0.040 |
Why?
|
| Hypercholesterolemia | 1 | 2019 | 159 | 0.040 |
Why?
|
| Transplantation Conditioning | 1 | 2020 | 372 | 0.040 |
Why?
|
| Vena Cava Filters | 1 | 2019 | 98 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 865 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2020 | 870 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2018 | 232 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 2763 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2018 | 179 | 0.040 |
Why?
|
| Ventricular Function, Right | 1 | 2017 | 146 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2016 | 122 | 0.030 |
Why?
|
| Hypercapnia | 1 | 2016 | 44 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2019 | 1237 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2018 | 395 | 0.030 |
Why?
|
| Multiple Organ Failure | 1 | 2016 | 53 | 0.030 |
Why?
|
| Hospitalization | 1 | 2022 | 880 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2019 | 759 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 743 | 0.030 |
Why?
|
| Pregnancy | 1 | 2023 | 3038 | 0.030 |
Why?
|
| beta-Arrestins | 1 | 2015 | 9 | 0.030 |
Why?
|
| Arrestins | 1 | 2015 | 9 | 0.030 |
Why?
|
| Testicular Neoplasms | 1 | 2017 | 113 | 0.030 |
Why?
|
| Calcineurin Inhibitors | 1 | 2016 | 53 | 0.030 |
Why?
|
| Hematocrit | 1 | 2015 | 68 | 0.030 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2015 | 39 | 0.030 |
Why?
|
| Calcium | 1 | 2020 | 1178 | 0.030 |
Why?
|
| Contraindications | 1 | 2015 | 70 | 0.030 |
Why?
|
| Transcriptome | 1 | 2020 | 655 | 0.030 |
Why?
|
| Platelet Activation | 1 | 2015 | 14 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 270 | 0.030 |
Why?
|
| Materials Testing | 1 | 2015 | 93 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 4309 | 0.030 |
Why?
|
| Miniaturization | 1 | 2015 | 14 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2016 | 253 | 0.030 |
Why?
|
| Body Height | 1 | 2015 | 100 | 0.030 |
Why?
|
| Proton Pump Inhibitors | 1 | 2015 | 34 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2015 | 70 | 0.030 |
Why?
|
| Endoscopy, Digestive System | 1 | 2015 | 69 | 0.030 |
Why?
|
| Sus scrofa | 1 | 2015 | 51 | 0.030 |
Why?
|
| Angiography | 1 | 2015 | 208 | 0.030 |
Why?
|
| Sirolimus | 1 | 2016 | 162 | 0.030 |
Why?
|
| Lactic Acid | 1 | 2015 | 92 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2015 | 120 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 276 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2015 | 131 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2017 | 323 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 1463 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2017 | 774 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2016 | 383 | 0.030 |
Why?
|
| Whole Blood Coagulation Time | 1 | 2013 | 7 | 0.030 |
Why?
|
| Ventricular Pressure | 1 | 2013 | 38 | 0.030 |
Why?
|
| Ventricular Fibrillation | 1 | 2013 | 68 | 0.030 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2013 | 65 | 0.030 |
Why?
|
| Class II Phosphatidylinositol 3-Kinases | 1 | 2012 | 9 | 0.030 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2012 | 46 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2013 | 223 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 2013 | 511 | 0.030 |
Why?
|
| Sex Factors | 1 | 2015 | 1073 | 0.030 |
Why?
|
| Tachycardia, Ventricular | 1 | 2013 | 124 | 0.030 |
Why?
|
| Mortality | 1 | 2013 | 149 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 1 | 2013 | 396 | 0.020 |
Why?
|
| Smoking | 1 | 2016 | 625 | 0.020 |
Why?
|
| Myocardial Contraction | 1 | 2013 | 252 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2014 | 465 | 0.020 |
Why?
|
| Pain Management | 1 | 2013 | 139 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2013 | 524 | 0.020 |
Why?
|
| Fibrosis | 1 | 2012 | 234 | 0.020 |
Why?
|
| Echocardiography | 1 | 2016 | 939 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2013 | 714 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 743 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2013 | 357 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2012 | 2884 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2012 | 1668 | 0.020 |
Why?
|